Study Evaluating the Efficacy of PN 400 BID and Celecoxib QD in Patients With Osteoarthritis of the Knee

This study is ongoing, but not recruiting participants.

Sponsored by:	Pozen
Information provided by:	Pozen
ClinicalTrials.gov Identifier:	NCT00665431

Purpose

We will evaluate the efficacy of PN 400 and an active comparator in patients that have Osteoarthritis of the knee.

Condition	Intervention	Phase
Osteoarthritis	Drug: PN 400 Drug: celebrex Drug: Placebo	Phase III

MedlinePlus related topics: Osteoarthritis

Study Type:	Interventional
Official Title:	Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN 400 BID and Celecoxib QD in Patients With Osteoarthritis of the Knee

Further study details as provided by Pozen:

Study Start Date:

April 2008

Eligibility

Criteria

Inclusion Criteria:

Male or non-pregnant female subjects ≥ 50 years of age with history of OA of the knee as well as other standard inclusion criteria for a study of this nature

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00665431

Locations

United States, Florida
Patient Interaction
Pompano Beach, Florida, United States, 33069

Sponsors and Collaborators

Pozen

More Information

Responsible Party:	Pozen ( Pozen )
Study ID Numbers:	PN400-309
Study First Received:	April 18, 2008
Last Updated:	September 8, 2008
ClinicalTrials.gov Identifier:	NCT00665431
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Osteoarthritis, Knee
Celecoxib
Musculoskeletal Diseases
Osteoarthritis

Joint Diseases
Arthritis
Rheumatic Diseases

ClinicalTrials.gov processed this record on January 16, 2009